Skip to search formSkip to main contentSkip to account menu

fulvestrant

Known as: 7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)estra-1,3,5(10)-triene-3,17-diol, 7a-[9-[(4,4,5,5,5,-Pentafluoropentyl)sulphinyl]nonyl]-estra-1,3,5(10)-triene-3,17b-diol, fulvestrant [Chemical/Ingredient] 
A synthetic estrogen receptor antagonist. Unlike tamoxifen (which has partial agonist effects) and the aromatase inhibitors (which reduce the… 
National Institutes of Health

Related topics

Related topics

16 relations
5 ML fulvestrant 50 MG/ML Prefilled Syringe [Faslodex]Drug AllergyEstrogen Receptor Antagonists [MoA]Hemorrhagic Disorders

Broader (3)

Antineoplastic Agents, HormonalEstradiolEstrogen Receptor Antagonists

Narrower (4)

FaslodexICI 182,780ZD9238ZM 182780

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Treatment after Progression on Fulvestrant among Metastatic Breast Cancer Patients in Clinical Practice: a Multicenter, Retrospective Study
Fulvestrant (Ful) is an effective and widely used agent for first- and second-line treatment of hormone receptor-positive, human… 
2016
2016
Correction: Exploiting MEK Inhibitor-Mediated Activation of ERα for Therapeutic Intervention in ER-Positive Ovarian Carcinoma
article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution… 
2014
2014
A novel anti-cancer agent, acetyltanshinone IIA, inhibits oestrogen receptor positive breast cancer cell growth by down-regulating the oestrogen receptor.
2011
2011
ERa-Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer
Authors' Affiliations: Departments of Cancer Biology, Medicine, Biostatistics, Radiology and Radiological Sciences, and Pathology… 
2007
2007
Synthesis, structure, and estrogenic activity of 4-amino-3-(2-methylbenzyl)coumarins on human breast carcinoma cells.
Review
2005
Review
2005
New developments in the treatment of postmenopausal breast cancer
Review
2005
Review
2005
Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast…
De novo insensitivity and acquired resistance to the selective oestrogen receptor modulator tamoxifen and the pure anti-oestrogen… 
2004
2004
Response to fulvestrant in heavily pretreated postmenopausal women:a single-center experience
Fulvestrant (`Faslodex') is a new estrogen receptor (ER) antagonist that has no agonist effects. It binds, blocks and accelerates… 
Review
2004
Review
2004
Fulvestrant: a new type of estrogen receptor antagonist for the treatment of advanced breast cancer.
Postmenopausal women with hormone receptor- positive tumors are candidates for endocrine treatment. Current treatment options… 
Review
2002
Review
2002
Evolving uses of hormonal agents for breast cancer therapy.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)